SURAKSHASuraksha Diagnostic Limited
Healthcare · Diagnostics & Research · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SURAKSHA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 20.7% YoY
- • Profit growth: 38.9% YoY
- • Debt/Equity: 0.54
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +25.3%
Bull case
- • Revenue growth: 20.7% YoY
- • Profit growth: 38.9% YoY
- • Debt/Equity: 0.54
- • Price vs SMA200: above
Bear case
- • Dividend yield: 0.16%
- • MACD: bearish
- • Price vs EMA21: below
- • 1-month return: -12.2%
Key risks
- • Dividend yield: 0.16%
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹17.01). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.